Dr Bhawna Sirohi

Dr Bhawna Sirohi

MBBS, FRCP

Consultant Medical Oncologist

About Me

I am currently working as Consultant medical oncologist at Barts Health NHS Trust. I am the program training director for medical oncology and clinical governance lead for breast oncology. My oncology career started in 1994 when I joined Tata Memorial Centre, India and then completed my training at Royal Marsden NHS Foundation Trust,UK. I have published more than 100 papers in national and international journals and lectured worldwide. I have a special interest in treating breast and HPB cancers. I have a keen interest in developing cancer care in low and middle-income group countries. I chair various cancer committee’s for ICMR and am member of the NCI-AIIMS advisory committee.

I am Secretary of EBMT Nuclear Accident Committee-as part of this have been involved with the UK Department of Health interdisciplinary Group on clinical care and service configuration following a radiation accident. I take a keen interest in raising funds for cancer research and awareness. I am the founder President of New India Cancer charity Initiative. I have previously been on the committee of David Adams Leukaemia Fund and am currently on management committee of CanSupport and a patron for voice of tobacco victims. I received the Royal Marsden award for excellence in 2000 for enhancing trusts reputation, the TMC-Women’s Cancer Initiative award in 2011, LBF Visionary award for excellence in 2011, Maulana Ilyasi Jameel Award in August 2013, Aadhi Abadi women achievers award in 2014. I am passionate about patient education, empowerment and delivering quality-evidence based care for my patients.

Research and Publications

Current Research : Triple negative breast cancer, Young women with breast cancer, Survivorship, Health Technology in cancer care, Cancer care in Low and middle income group countries and gall bladder cancer

Publications: A randomised comparative trial of infusional ECisF (epirubicin, cisplatin and infusional 5FU) vs conventional FEC (5FU, epirubicin and cyclophosphamide) as adjuvant chemotherapy in early breast cancer: The TRAFIC (TRial of Adjuvant 5FU Infusional Chemotherapy) trial. Ann Oncol. 2010 Aug; 21(8): 1623-9. Epub 2010 Jan 21.

Survival of women with inflammatory breast cancer: a large population-based study. Ann Oncol. 2014 Jun;25(6):1143-51

Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer. Future Oncol. 2015;11(6):923-31.

Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer. Breast Cancer Res. 2007 Oct 26; 9(5): 112

Buparlisib in breast cancer. Future Oncol. 2015;11(10):1463-70. Bevacizumab in the treatment of breast cancer. Expert Rev Anticancer Ther. 2008 Oct;8(10): 1559-68

Ipsilateral Breast tumour recurrence: current practice and recommendations. Breast J. 2009 May-Jun; 15(3): 268-78.

Evolution of pancreatoduodenectomy in a tertiary cancer center in India: improved results from service reconfiguration. Pancreatology. 2013 Jan-Feb;13(1):63-71.

Use of gemcitabine-platinum in Indian patients with advanced gall bladder cancer. Future Oncol. 2015;11(8):1191-2000.

Neoadjuvant chemotherapy in patients with locally advanced gallbladder cancer. Future Oncol. 2015;11(10):1501-9

Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin. Endocr Relat Cancer. 2010 Jan 29; 17(1): R75-90

Pancreatic neuroendocrine tumors Indian J Gastroenterol. 2013 Jan; 32(1): 3-17.

LOC 95 Harley Street
LOC at Chelsea